These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17488363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
    Hwang YC, Lee EY, Lee WJ, Cha BS, Yoon KH, Park KS, Lee MK.
    Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
    Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP.
    J Am Coll Cardiol; 2007 Apr 24; 49(16):1696-704. PubMed ID: 17448371
    [Abstract] [Full Text] [Related]

  • 6. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G.
    J Intern Med; 2007 Mar 24; 261(3):293-305. PubMed ID: 17305652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.
    Exp Clin Endocrinol Diabetes; 2011 Feb 24; 119(2):63-8. PubMed ID: 21031343
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct 24; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 11. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy.
    Zhu C, Liang QL, Hu P, Wang YM, Luo GA.
    Talanta; 2011 Sep 30; 85(4):1711-20. PubMed ID: 21872008
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC.
    Clin Endocrinol (Oxf); 2007 Feb 30; 66(2):282-9. PubMed ID: 17224000
    [Abstract] [Full Text] [Related]

  • 13. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.
    Clin Endocrinol (Oxf); 2006 Dec 30; 65(6):722-8. PubMed ID: 17121522
    [Abstract] [Full Text] [Related]

  • 14. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA.
    Clin Ther; 2012 Aug 30; 34(8):1761-71. PubMed ID: 22795925
    [Abstract] [Full Text] [Related]

  • 15. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR.
    Horm Metab Res; 2012 Nov 30; 44(12):914-8. PubMed ID: 22723267
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec 30; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 17. Effect of various diuretic treatments on rosiglitazone-induced fluid retention.
    Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, Rosiglitazone Fluid Retention Study Group.
    J Am Soc Nephrol; 2006 Dec 30; 17(12):3482-90. PubMed ID: 17093067
    [Abstract] [Full Text] [Related]

  • 18. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.
    Dunn FL, Higgins LS, Fredrickson J, DePaoli AM, INT131-004 study group.
    J Diabetes Complications; 2011 Dec 30; 25(3):151-8. PubMed ID: 20739195
    [Abstract] [Full Text] [Related]

  • 19. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A.
    Acta Med Indones; 2006 Dec 30; 38(3):160-6. PubMed ID: 17119268
    [Abstract] [Full Text] [Related]

  • 20. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Am J Cardiol; 2006 Mar 01; 97(5):646-50. PubMed ID: 16490430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.